Chronic traumatic encephalopathy (CTE) is a progressive neurodegenerative disease caused by repetitive traumatic brain injury (TBI), commonly observed in contact sport athletes, military veterans, and individuals with a history of head trauma. CTE is characterized by the accumulation of hyperphosphorylated tau (p-tau) protein in the brain, leading to cognitive, behavioral, and motor impairments. First described in boxers in the 1920s as "dementia pugilistica," CTE has now been identified in athletes from multiple sports including American football, ice hockey, soccer, rugby, and wrestling, as well as in military personnel with blast exposure or combat-related head injuries. [1]
The development of CTE is strongly associated with repetitive mild traumatic brain injury:
| Risk Factor | Description | Evidence Strength |
|---|---|---|
| Repetitive mild TBI | Multiple concussions or subconcussive impacts | Strong |
| Contact sport participation | American football, boxing, ice hockey, soccer, rugby | Strong |
| Military service | Blast exposure, combat-related head injuries | Strong |
| History of childhood head trauma | Earlier exposure increases cumulative risk | Moderate |
| Apolipoprotein E ε4 | Genetic risk factor | Moderate |
Epidemiological studies demonstrate a clear dose-response relationship between head impact exposure and CTE risk:
The seminal study by McKee et al. demonstrated that among 202 former American football players from the United States, CTE was diagnosed in 177 (87%) of players at all levels of play, with the disease present in 99% of NFL players examined. [1:1]
The neuropathological diagnosis of CTE is based on a constellation of specific findings[2]:
These features distinguish CTE from other tauopathies, particularly Alzheimer's disease, where tau pathology follows a predictable pattern starting in the entorhinal cortex.
Additional pathological findings commonly observed in CTE include:
| Feature | Prevalence | Significance |
|---|---|---|
| Beta-amyloid deposition | ~40% of cases | Less common than in AD |
| TDP-43 inclusions | ~80% of cases | Distinguishes from AD |
| α-Synuclein inclusions | ~20% of cases | May indicate comorbid pathology |
| White matter rarefaction | Common | Reflects demyelination and axonal loss |
| Cerebellar involvement | Stage IV | Late-stage feature |
The Mackenzie-Smith staging system defines progressive pathological changes[2:1]:
| Stage | Pathological Features | Clinical Correlation |
|---|---|---|
| Stage I | Perivascular p-tau in sulcal depths, focal NFTs | Often asymptomatic |
| Stage II | Multiple cortical areas affected, NFTs in limbic regions | Mood and behavioral changes |
| Stage III | Widespread cortical involvement, NFTs in diencephalon | Cognitive impairment |
| Stage IV | Severe global atrophy, NFTs in brainstem, cerebellum | Dementia, motor symptoms |
The hyperphosphorylation of tau in CTE involves multiple kinase and phosphatase systems:
Kinase activation:
Phosphatase dysfunction:
Axonal transport impairment:
Chronic neuroinflammation is a central feature of CTE pathogenesis[3]:
The mechanical forces in repetitive TBI cause:
| Feature | Acute TBI |
|---|---|
| Onset | Immediate mechanical damage |
| Primary injury | Contusion, hemorrhage, diffuse axonal injury |
| Secondary injury | Edema, ischemia, excitotoxicity |
| Inflammatory response | Acute, resolving over weeks |
| Recovery | Typically reversible to some degree |
| Feature | Repetitive TBI / CTE |
|---|---|
| Onset | Cumulative subclinical damage over years |
| Primary injury | No single identifiable event |
| Inflammatory response | Chronic, persistent |
| Pathology | Progressive tau pathology |
| Progression | Neurodegeneration continues years after cessation of trauma |
The clinical progression of CTE typically involves three core domains[4]:
1. Cognitive impairment:
2. Behavioral changes:
3. Motor symptoms:
The National Institute of Neurological Disorders and Stroke (NINDS) has established diagnostic criteria for CTE[5]:
Proposed diagnostic criteria:
Current and emerging biomarkers for CTE include[6][7]:
| Modality | Findings in CTE |
|---|---|
| MRI | White matter hyperintensities, cortical atrophy, ventricular enlargement |
| PET | Tau ligand binding (Flortaucipir, MK-6240) showing sulcal pattern |
| CSF | Elevated total tau, p-tau181, neurofilament light chain (NfL) |
| Blood | Elevated NfL, p-tau181, glial fibrillary acidic protein (GFAP) |
| DTI | White matter microstructure abnormalities |
CTE must be distinguished from:
Primary prevention approaches include:
Current management strategies include:
Investigational therapies include:
McKee AC, et al. The spectrum of disease in chronic traumatic encephalopathy. Acta Neuropathologica. 2013. ↩︎ ↩︎
Mackenzie IR, et al. Neuropathologic diagnostic criteria for chronic traumatic encephalopathy. Acta Neuropathologica. 2016. ↩︎ ↩︎
Stewart ES, et al. Neuroinflammation in chronic traumatic encephalopathy. Brain Pathol. 2022. ↩︎
Tarnutzer AA, et al. Clinical presentation and diagnosis of chronic traumatic encephalopathy. Lancet Neurol. 2023. ↩︎
NINDS CTE Criteria Working Group. NINDS diagnostic criteria for chronic traumatic encephalopathy. Neurology. 2021. ↩︎
Cox CS, Blennow K. Biomarkers for chronic traumatic encephalopathy. Nat Rev Neurol. 2022. ↩︎
Karantali E, et al. Neuroimaging biomarkers in chronic traumatic encephalopathy. Radiology. 2023. ↩︎